Peptide vaccination therapy for malignant glioma

Brain and Nerve

Volumn 59, Issue 3, 2007, Pages 251-261

  Yamanaka, Ryuya ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glioma; Immunotherapy; Peptide

Indexed keywords

CANCER VACCINE; CYCLOPHILIN B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MULTIDRUG RESISTANCE PROTEIN 3; PARATHYROID HORMONE RELATED PROTEIN; PROSTATE STEM CELL ANTIGEN; PROTEIN P56; SQUAMOUS CELL CARCINOMA ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; CENTRAL NERVOUS SYSTEM; GLIOMA; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; VACCINES, SUBUNIT;

EID: 33947432815     PISSN: 00068969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Andersen MH, Ostergaard PL, Becker JC, thor Straten P: Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61: 869-872, 2000
2. Azuma K, Shichijo S, Maeda Y, Nonaka Y, Itoh K et al: Mutated p53 gene encodes a non-mutated epitope recognized by HLA-B4601-restrited and tumor-reactive CTLs at tumor site. Cancer Res 63: 854-858, 2003
3. Banchereau J, Briere F, Caux C, Davoust J, Palucka K, et al: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000
4. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Kaufman HL, et al: Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24: 1169-1177, 2006
5. Chi DD, Merchant RE, Rand R, Conrad AJ, Hoon DS, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150: 2143-2152, 1997
6. Chattopadhyay S, Chakraborty NG, Mukherji B: Regulatory T cells and tumor immunity. Cancer Immunol Immunother 54: 1153-1161, 2005
7. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Mulligan RC, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90: 3539-3543, 1993
8. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117, 1995
9. Fischer U, Struss AK, Hemmer D, Pallasch CP, Meese E, et al: Glioma expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls. Clin Exp Immunol 126: 206-213, 2001
10. Fong L, Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245-273, 2000
11. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Nelson SF et al: Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503-6510, 2004
12. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Stokoe D, et al: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: 880-887, 2005
13. Hegi ME, Diserens AC, Gorlia T, Hamou MF, Stupp R, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005
14. Imaizumi T, Kuramoto T, Matsunaga K, Shichijo S, Itoh K, et al: Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer 83: 760-764, 1999
15. Ito M, Shichijo S, Miyagi Y, Kobayashi T, Itoh K, et al: Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 88: 63 3-639, 2000
16. Jager E, Chen YT, Drijfhout JW, Karbach J, Knuth A, et al: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-270, 1998
17. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rosenberg SA, et al: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180: 347-352, 1994
18. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rosenberg SA, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91: 3515-3519, 1994
19. Kawakami Y, Robbins PF, Wang X, Tupesis JP, Rosenberg SA, et al: Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, HLA-A2, and HLA-A3 alleles. J Immunol 161: 6985-6992, 1998
20. Kikuchi M, Nakao M, Inoue Y, Matsunaga K, Itoh K, et al: Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 81: 459-466, 1999
21. Kikuchi T, Akasaki Y, Irie M, Homma S, Ohno T, et al: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50: 337-344, 2001
22. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Ohno T, et al: Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27: 452-459, 2004
23. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, Bigner DD, et al: Tumor antigens in astrocytic gliomas. Glia 15: 244-256, 1995
24. Kuramoto T: Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J 44: 43-51, 1997
25. Liang Y, Diehn M, Watson N, Bollen AW, Israel MA, et al: Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814-5819, 2005
26. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Mischel PS, et al: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024, 2005
27. Minev B, Hipp J, Firat H, Schmidt JD, Zanetti M, et al: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 97: 4796-4801, 2000
28. Mine T, Gouhara R, Hida N, Imai N, Yamana H, et al: Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 94: 548-556, 2003
29. Murayama K, Kobayashi T, Imaizumi T, Matsunaga K, Itoh K, et al: Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 23: 511-518, 2000
30. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Itoh K, et al: Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 164: 2565-2574, 2000
31. Nestle FO, Alijagic S, Gilliet M, Sun Y, Schadendorf D, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998
32. Nigro JM, Misra A, Zhang L, Smirnov I, Aldape KD, et al: Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65: 1678-1686, 2005
33. Noguchi M, Itoh K, Suekane S, Yao A, Noda S, et al: Phase I traial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 95: 77-84, 2004
34. Nutt CL, Mani DR, Betensky RA, Tamayo P, Louis DN, et al: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602-1607, 2003
35. Ohminami H, Yasukawa M, Fujita S: HLA class I-restricted lysis of leukemia cells by a CD8(+)cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95: 286-293, 2000
36. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H: Identification of a novel HLA-A* 0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8: 2851-2855, 2002
37. Oka Y, Tsuboi A, Taguchi T, Osaki T, Sugiyama H, et al: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101: 13885-13890, 2004
38. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Eberlein TJ, et al: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/ neu-derived peptide. Proc Natl Acad Sci U S A 92: 432-436, 1995
39. Rich JN, Hans C, Jones B, Iversen ES, West M, et al: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65: 4051-4058, 2005
40. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, White DE, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998
41. Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Van Gool SW, et al: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91: 1656-1662, 2004
42. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Bigner DD, et al: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 93: 10399-10404, 1996
43. Sahin U, Koslowski M, Tureci O, Eberle T, Pfreundschuh M, et al: Expression of cancer testis genes in human brain tumors. Clin Cancer Res 6: 3916-3922, 2000
44. Sato Y, Shomura H, Maeda Y, Mine T, Todo S, et al: Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94: 802-808, 2003
45. Sakaguchi S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352, 2005
46. Scarcella DL, Chow CW, Gonzales MF, Economou C, Ashley DM, et al: Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 5: 335-341, 1999
47. Shichijo S, Nakao M, Imai Y, Takasu H, Itoh K, et al: A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187: 277-288, 1998
48. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Merrill P, et al: Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22: 4474-4485, 2004
49. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Rao MR, et al: Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 24: 7073-7083, 2005
50. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1991
51. Stupp R, Mason WP, van den Bent MJ, Weller M, Mirimanoff RO, et al; European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005
52. van der Bruggen P, Traversari C, Chomez P, Lurquin C, Boon T, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991
53. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Boon T, et al: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182: 689-698, 1995
54. Visseren MJ, van der Burg SH, van der Voort EI, Brandt RM, Kast WM, et al: Identification of HLA-A* 0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 73: 125-130, 1997
55. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679, 1999
56. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA: Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 183: 1131-1140, 1996
57. Woo EY, Chu CS, Goletz TJ, Schlienger K, June CH: Regulatory CD4(+)CD25(+)T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772, 2001
58. Wong KK, Chang YM, Tsang YT, Perlaky L, Lau CC, et al: Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res 65: 76-84, 2005
59. Yang D, Nakao M, Shichijo S, Sasatomi T, Itoh K, et al: Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59: 4056-4063, 1999
60. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG: Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus -mediated by complementary DNA. J Neurosurg 94: 474-481, 2001
61. Yamanaka R, Yajima N, Abe T, Tsuchiya N, Tanaka R, et al: Dendritic cell-based glioma immunotherapy (Review). Int J Oncol 23: 5-15, 2003
62. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Tanaka R, et al: Vaccination of recurrent glioma patients with tumor-lysate pulsed dendritic cells elicits immune responses: results of clinical phase I/II trial. Br J Cancer 89: 1172-1179, 2003
63. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Tanaka R, et al: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11: 4160-4167, 2005
64. Yamanaka R, Arao T, Yajima N, Tsuchiya N, Nishio K, et al: Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 25: 5994-6002, 2006
65. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Tanaka R, et al: Immunological evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11: 5900-5911, 2005
66. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Black KL, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61: 842-847, 2001
67. Yu JS, Liu G, Ying H, Yong WH, Wheeler CJ, et al: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64: 4973-4979, 2004